bioRxiv Science⌕ Search

Biology subjects

Gennarelli, M.

Publications and source records attributed to Gennarelli, M..

3 recordsLinked to original sources

The complementary roles of rare variant burden scores and common variant polygenic risk scores in genetic risk prediction of complex disorders

Polygenic risk scores (PRS) derived from common variants have improved risk prediction for complex disorders, however they capture only a fraction of heritability. One of the reasons for this is the exclusion of rare variants, despite growing evidence of their substantial contribution to genetic liability. Here we implemented the Independent Outlier Gene Count (IOGC) - a score summarising the individual burden of rare variants associated with outlying gene expression - and measured the amount of liability explained by this rare-variant score, alone and in combination with common-variant PRS, for schizophrenia, major depressive disorder, and hypertrophic cardiomyopathy in the UK Biobank. IOGC and PRS were minimally correlated (|r|<0.2), indicating the two scores capture complementary information. For schizophrenia, a model including both IOGC and PRS explained 1.13 times the adjusted liability than PRS alone. For hypertrophic cardiomyopathy, a 1.48-fold increase was observed for the combined model. People with high IOGC showed a 64% and 46% higher positive predictive value for schizophrenia and HCM, respectively, as compared to those with low IOGC. No improvement was observed for depression. These findings demonstrate that integrating rare- and common-variant scores enhances genetic risk prediction for complex conditions with a strong genetic component, supporting the inclusion of rare variant burden metrics in future genomic risk models.

genomics↗

Investigating an in-silico approach for prioritizing antidepressant drug prescription based on drug-induced expression profiles and predicted gene expression

In clinical practice, antidepressant prescription is a trial and error approach, which is time consuming and discomforting for patients. This study investigated an in-silico approach for ranking antidepressants based on their hypothetical likelihood of efficacy. We determined the transcriptomic profile of citalopram remitters by performing a transcriptomic-wide association study on STAR*D data (N =1163). The transcriptional profile of remitters was compared with 21 antidepressant-induced gene expression profiles in five human cell lines available in the connectivity map database. Spearman correlation, Pearson correlation, and the Kolmogorov Smirnov test were used to determine the similarity between antidepressant-induced profiles and remitter profiles, subsequently calculating the average rank of antidepressants across the three methods and a p-value for each rank by using a permutation procedure. The drugs with the top ranks were those having high positive correlation with the expression profiles of remitters and they may have higher chances of efficacy in the tested patients. In MCF7 (breast cancer cell line), escitalopram had the highest average rank, with an average rank higher than expected by chance (p=0.0014). In A375 (human melanoma) and PC3 (prostate cancer) cell lines, escitalopram and citalopram emerged as the second highest ranked antidepressants, respectively (p=0.0310 and 0.0276, respectively). In HA1E (kidney) and HT29 (colon cancer) cell types, citalopram and escitalopram did not fall among top antidepressants. The correlation between citalopram remitters and (es)citalopram-induced expression profiles in three cell lines suggests that our approach may be useful and with future improvements it can be applicable at the individual level to tailor treatment prescription.

bioinformatics↗

Genome-wide analysis of RNA editing levels in human blood identified interactions with mRNA processing genes and suggested correlations with biological and drug-related variables

BackgroundA-to-I RNA editing is a co-/post-transcriptional modification catalyzed by ADAR enzymes, that deaminates Adenosines (A) into Inosines (I). Most of known editing events are located within inverted ALU repeats, but they also occur in coding sequences and may alter the function of encoded proteins. RNA editing contributes to generate transcriptomic diversity and it is found altered in cancer, autoimmune and neurological disorders. Emerging evidences indicate that editing process could be influenced by genetic variations, biological and environmental variables.\n\nResultsWe analyzed RNA editing levels in human blood using RNA-seq data from 459 healthy individuals and identified 2,079 sites consistently edited in this tissue. As expected, analysis of gene expression revealed that ADAR is the major contributor to editing on these sites, explaining [~]13% of observed variability. After removing ADAR effect, we found significant associations for 1,122 genes, mainly involved in RNA processing. These genes were significantly enriched in genes encoding proteins interacting with ADARs, including 276 potential ADARs interactors and 9 ADARs direct partners. In addition, our analysis revealed several factors potentially influencing RNA editing in blood, including cell composition, age, Body Mass Index, smoke and alcohol consumption. Finally, we identified genetic loci associated with editing levels, including known ADAR eQTLs and a small region on chromosome 7, containing LOC730338, a lincRNA gene that appears to modulate ADARs mRNA expression.\n\nConclusionsOur data provides a detailed picture of the most relevant RNA editing events and their variability in human blood, giving interesting insights on potential mechanisms behind this post-transcriptional modification and its regulation in this tissue.

genomics↗